CN1908162A - Serum-free culture medium of human embryo kidney (HEK) 293 cell - Google Patents
Serum-free culture medium of human embryo kidney (HEK) 293 cell Download PDFInfo
- Publication number
- CN1908162A CN1908162A CNA2006100301108A CN200610030110A CN1908162A CN 1908162 A CN1908162 A CN 1908162A CN A2006100301108 A CNA2006100301108 A CN A2006100301108A CN 200610030110 A CN200610030110 A CN 200610030110A CN 1908162 A CN1908162 A CN 1908162A
- Authority
- CN
- China
- Prior art keywords
- acid
- vitamin
- serum
- free medium
- hek
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 210000003734 kidney Anatomy 0.000 title claims abstract description 10
- 210000001161 mammalian embryo Anatomy 0.000 title claims description 9
- 239000004017 serum-free culture medium Substances 0.000 title 1
- 239000012679 serum free medium Substances 0.000 claims abstract description 21
- 150000002632 lipids Chemical class 0.000 claims abstract description 16
- 239000000203 mixture Substances 0.000 claims abstract description 14
- 150000001413 amino acids Chemical class 0.000 claims abstract description 10
- 238000004113 cell culture Methods 0.000 claims abstract description 10
- 229940088594 vitamin Drugs 0.000 claims abstract description 8
- 229930003231 vitamin Natural products 0.000 claims abstract description 8
- 235000013343 vitamin Nutrition 0.000 claims abstract description 8
- 239000011782 vitamin Substances 0.000 claims abstract description 8
- 102000004877 Insulin Human genes 0.000 claims abstract description 6
- 108090001061 Insulin Proteins 0.000 claims abstract description 6
- 150000003839 salts Chemical class 0.000 claims abstract description 5
- 239000000126 substance Substances 0.000 claims abstract description 4
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 claims description 11
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 claims description 8
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 claims description 8
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 claims description 8
- 229930195722 L-methionine Natural products 0.000 claims description 8
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 claims description 8
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 8
- JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 claims description 8
- RVGRUAULSDPKGF-UHFFFAOYSA-N Poloxamer Chemical compound C1CO1.CC1CO1 RVGRUAULSDPKGF-UHFFFAOYSA-N 0.000 claims description 7
- 229920001993 poloxamer 188 Polymers 0.000 claims description 7
- 150000003722 vitamin derivatives Chemical class 0.000 claims description 7
- -1 Polyoxyethylene Polymers 0.000 claims description 6
- 229940024606 amino acid Drugs 0.000 claims description 6
- 235000001014 amino acid Nutrition 0.000 claims description 6
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 claims description 6
- 229910017053 inorganic salt Inorganic materials 0.000 claims description 6
- LXNHXLLTXMVWPM-UHFFFAOYSA-N pyridoxine Chemical compound CC1=NC=C(CO)C(CO)=C1O LXNHXLLTXMVWPM-UHFFFAOYSA-N 0.000 claims description 6
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 claims description 5
- 239000007995 HEPES buffer Substances 0.000 claims description 5
- 229920003171 Poly (ethylene oxide) Polymers 0.000 claims description 5
- 102000002070 Transferrins Human genes 0.000 claims description 5
- 108010015865 Transferrins Proteins 0.000 claims description 5
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 claims description 5
- 150000002505 iron Chemical class 0.000 claims description 5
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 claims description 4
- 239000001763 2-hydroxyethyl(trimethyl)azanium Substances 0.000 claims description 4
- 235000019743 Choline chloride Nutrition 0.000 claims description 4
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 claims description 4
- CKLJMWTZIZZHCS-UHFFFAOYSA-N D-OH-Asp Natural products OC(=O)C(N)CC(O)=O CKLJMWTZIZZHCS-UHFFFAOYSA-N 0.000 claims description 4
- 229920002307 Dextran Polymers 0.000 claims description 4
- 229910000608 Fe(NO3)3.9H2O Inorganic materials 0.000 claims description 4
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 4
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 claims description 4
- SQUHHTBVTRBESD-UHFFFAOYSA-N Hexa-Ac-myo-Inositol Natural products CC(=O)OC1C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C1OC(C)=O SQUHHTBVTRBESD-UHFFFAOYSA-N 0.000 claims description 4
- CKLJMWTZIZZHCS-UWTATZPHSA-N L-Aspartic acid Natural products OC(=O)[C@H](N)CC(O)=O CKLJMWTZIZZHCS-UWTATZPHSA-N 0.000 claims description 4
- FFEARJCKVFRZRR-UHFFFAOYSA-N L-Methionine Natural products CSCCC(N)C(O)=O FFEARJCKVFRZRR-UHFFFAOYSA-N 0.000 claims description 4
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 claims description 4
- ODKSFYDXXFIFQN-BYPYZUCNSA-N L-arginine Chemical compound OC(=O)[C@@H](N)CCCN=C(N)N ODKSFYDXXFIFQN-BYPYZUCNSA-N 0.000 claims description 4
- 229930064664 L-arginine Natural products 0.000 claims description 4
- 235000014852 L-arginine Nutrition 0.000 claims description 4
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 claims description 4
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 claims description 4
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 claims description 4
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 claims description 4
- 229930182844 L-isoleucine Natural products 0.000 claims description 4
- 239000004395 L-leucine Substances 0.000 claims description 4
- 235000019454 L-leucine Nutrition 0.000 claims description 4
- 229930182821 L-proline Natural products 0.000 claims description 4
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 claims description 4
- DFPAKSUCGFBDDF-UHFFFAOYSA-N Nicotinamide Chemical compound NC(=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-UHFFFAOYSA-N 0.000 claims description 4
- 239000004473 Threonine Substances 0.000 claims description 4
- 229930003779 Vitamin B12 Natural products 0.000 claims description 4
- 229930003756 Vitamin B7 Natural products 0.000 claims description 4
- YZXBAPSDXZZRGB-DOFZRALJSA-N arachidonic acid Chemical compound CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O YZXBAPSDXZZRGB-DOFZRALJSA-N 0.000 claims description 4
- 229960005261 aspartic acid Drugs 0.000 claims description 4
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 claims description 4
- SGMZJAMFUVOLNK-UHFFFAOYSA-M choline chloride Chemical compound [Cl-].C[N+](C)(C)CCO SGMZJAMFUVOLNK-UHFFFAOYSA-M 0.000 claims description 4
- 229960003178 choline chloride Drugs 0.000 claims description 4
- AGVAZMGAQJOSFJ-WZHZPDAFSA-M cobalt(2+);[(2r,3s,4r,5s)-5-(5,6-dimethylbenzimidazol-1-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] [(2r)-1-[3-[(1r,2r,3r,4z,7s,9z,12s,13s,14z,17s,18s,19r)-2,13,18-tris(2-amino-2-oxoethyl)-7,12,17-tris(3-amino-3-oxopropyl)-3,5,8,8,13,15,18,19-octamethyl-2 Chemical compound [Co+2].N#[C-].[N-]([C@@H]1[C@H](CC(N)=O)[C@@]2(C)CCC(=O)NC[C@@H](C)OP(O)(=O)O[C@H]3[C@H]([C@H](O[C@@H]3CO)N3C4=CC(C)=C(C)C=C4N=C3)O)\C2=C(C)/C([C@H](C\2(C)C)CCC(N)=O)=N/C/2=C\C([C@H]([C@@]/2(CC(N)=O)C)CCC(N)=O)=N\C\2=C(C)/C2=N[C@]1(C)[C@@](C)(CC(N)=O)[C@@H]2CCC(N)=O AGVAZMGAQJOSFJ-WZHZPDAFSA-M 0.000 claims description 4
- BVTBRVFYZUCAKH-UHFFFAOYSA-L disodium selenite Chemical compound [Na+].[Na+].[O-][Se]([O-])=O BVTBRVFYZUCAKH-UHFFFAOYSA-L 0.000 claims description 4
- 239000008103 glucose Substances 0.000 claims description 4
- 229960002989 glutamic acid Drugs 0.000 claims description 4
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 claims description 4
- 235000003969 glutathione Nutrition 0.000 claims description 4
- 229960003180 glutathione Drugs 0.000 claims description 4
- 229960002885 histidine Drugs 0.000 claims description 4
- 229960000890 hydrocortisone Drugs 0.000 claims description 4
- 229960000367 inositol Drugs 0.000 claims description 4
- CDAISMWEOUEBRE-GPIVLXJGSA-N inositol Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](O)[C@@H]1O CDAISMWEOUEBRE-GPIVLXJGSA-N 0.000 claims description 4
- 229960000310 isoleucine Drugs 0.000 claims description 4
- 229960003136 leucine Drugs 0.000 claims description 4
- 229960004452 methionine Drugs 0.000 claims description 4
- 229960003966 nicotinamide Drugs 0.000 claims description 4
- 235000005152 nicotinamide Nutrition 0.000 claims description 4
- 239000011570 nicotinamide Substances 0.000 claims description 4
- 229960002429 proline Drugs 0.000 claims description 4
- CDAISMWEOUEBRE-UHFFFAOYSA-N scyllo-inosotol Natural products OC1C(O)C(O)C(O)C(O)C1O CDAISMWEOUEBRE-UHFFFAOYSA-N 0.000 claims description 4
- 239000011734 sodium Substances 0.000 claims description 4
- 239000011780 sodium chloride Substances 0.000 claims description 4
- 229960001471 sodium selenite Drugs 0.000 claims description 4
- 235000015921 sodium selenite Nutrition 0.000 claims description 4
- 239000011781 sodium selenite Substances 0.000 claims description 4
- 229960002898 threonine Drugs 0.000 claims description 4
- 229960004799 tryptophan Drugs 0.000 claims description 4
- 235000019163 vitamin B12 Nutrition 0.000 claims description 4
- 239000011715 vitamin B12 Substances 0.000 claims description 4
- 235000011912 vitamin B7 Nutrition 0.000 claims description 4
- 239000011735 vitamin B7 Substances 0.000 claims description 4
- OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 claims description 3
- 229960000304 folic acid Drugs 0.000 claims description 3
- 235000019152 folic acid Nutrition 0.000 claims description 3
- 239000011724 folic acid Substances 0.000 claims description 3
- 239000004615 ingredient Substances 0.000 claims description 3
- RADKZDMFGJYCBB-UHFFFAOYSA-N pyridoxal hydrochloride Natural products CC1=NC=C(CO)C(C=O)=C1O RADKZDMFGJYCBB-UHFFFAOYSA-N 0.000 claims description 3
- 239000011726 vitamin B6 Substances 0.000 claims description 3
- 235000019158 vitamin B6 Nutrition 0.000 claims description 3
- 229940011671 vitamin b6 Drugs 0.000 claims description 3
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 claims description 2
- TWJNQYPJQDRXPH-UHFFFAOYSA-N 2-cyanobenzohydrazide Chemical compound NNC(=O)C1=CC=CC=C1C#N TWJNQYPJQDRXPH-UHFFFAOYSA-N 0.000 claims description 2
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 claims description 2
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 claims description 2
- ZAKOWWREFLAJOT-CEFNRUSXSA-N D-alpha-tocopherylacetate Chemical compound CC(=O)OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C ZAKOWWREFLAJOT-CEFNRUSXSA-N 0.000 claims description 2
- 239000011626 DL-alpha-tocopherylacetate Substances 0.000 claims description 2
- 235000001809 DL-alpha-tocopherylacetate Nutrition 0.000 claims description 2
- OYHQOLUKZRVURQ-HZJYTTRNSA-N Linoleic acid Chemical compound CCCCC\C=C/C\C=C/CCCCCCCC(O)=O OYHQOLUKZRVURQ-HZJYTTRNSA-N 0.000 claims description 2
- 235000021360 Myristic acid Nutrition 0.000 claims description 2
- TUNFSRHWOTWDNC-UHFFFAOYSA-N Myristic acid Natural products CCCCCCCCCCCCCC(O)=O TUNFSRHWOTWDNC-UHFFFAOYSA-N 0.000 claims description 2
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 claims description 2
- 239000005642 Oleic acid Substances 0.000 claims description 2
- 235000021355 Stearic acid Nutrition 0.000 claims description 2
- DTOSIQBPPRVQHS-PDBXOOCHSA-N alpha-linolenic acid Chemical compound CC\C=C/C\C=C/C\C=C/CCCCCCCC(O)=O DTOSIQBPPRVQHS-PDBXOOCHSA-N 0.000 claims description 2
- 235000020661 alpha-linolenic acid Nutrition 0.000 claims description 2
- 229940114079 arachidonic acid Drugs 0.000 claims description 2
- 235000021342 arachidonic acid Nutrition 0.000 claims description 2
- FAPWYRCQGJNNSJ-CTWWJBIBSA-L calcium;3-[[(2s)-2,4-dihydroxy-3,3-dimethylbutanoyl]amino]propanoate Chemical compound [Ca+2].OCC(C)(C)[C@H](O)C(=O)NCCC([O-])=O.OCC(C)(C)[C@H](O)C(=O)NCCC([O-])=O FAPWYRCQGJNNSJ-CTWWJBIBSA-L 0.000 claims description 2
- 235000012000 cholesterol Nutrition 0.000 claims description 2
- 230000001186 cumulative effect Effects 0.000 claims description 2
- IPCSVZSSVZVIGE-UHFFFAOYSA-N hexadecanoic acid Chemical compound CCCCCCCCCCCCCCCC(O)=O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 claims description 2
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 claims description 2
- 229960004232 linoleic acid Drugs 0.000 claims description 2
- 229960004488 linolenic acid Drugs 0.000 claims description 2
- KQQKGWQCNNTQJW-UHFFFAOYSA-N linolenic acid Natural products CC=CCCC=CCC=CCCCCCCCC(O)=O KQQKGWQCNNTQJW-UHFFFAOYSA-N 0.000 claims description 2
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 claims description 2
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 claims description 2
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 claims description 2
- SECPZKHBENQXJG-FPLPWBNLSA-N palmitoleic acid Chemical compound CCCCCC\C=C/CCCCCCCC(O)=O SECPZKHBENQXJG-FPLPWBNLSA-N 0.000 claims description 2
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 claims description 2
- 229920000053 polysorbate 80 Polymers 0.000 claims description 2
- 239000008117 stearic acid Substances 0.000 claims description 2
- 229940042585 tocopherol acetate Drugs 0.000 claims description 2
- 239000001963 growth medium Substances 0.000 abstract description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 abstract 2
- 102000004338 Transferrin Human genes 0.000 abstract 1
- 108090000901 Transferrin Proteins 0.000 abstract 1
- 238000012258 culturing Methods 0.000 abstract 1
- 229940125396 insulin Drugs 0.000 abstract 1
- 239000012581 transferrin Substances 0.000 abstract 1
- 210000004027 cell Anatomy 0.000 description 18
- 210000002966 serum Anatomy 0.000 description 14
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 6
- 239000002609 medium Substances 0.000 description 6
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 4
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 4
- AGBQKNBQESQNJD-SSDOTTSWSA-N (R)-lipoic acid Chemical compound OC(=O)CCCC[C@@H]1CCSS1 AGBQKNBQESQNJD-SSDOTTSWSA-N 0.000 description 3
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 3
- CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 description 3
- AGBQKNBQESQNJD-UHFFFAOYSA-N alpha-Lipoic acid Natural products OC(=O)CCCCC1CCSS1 AGBQKNBQESQNJD-UHFFFAOYSA-N 0.000 description 3
- 235000019136 lipoic acid Nutrition 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 238000000034 method Methods 0.000 description 3
- 239000002994 raw material Substances 0.000 description 3
- 229960001153 serine Drugs 0.000 description 3
- 229960002663 thioctic acid Drugs 0.000 description 3
- 210000001541 thymus gland Anatomy 0.000 description 3
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 2
- 108090000723 Insulin-Like Growth Factor I Proteins 0.000 description 2
- 102000013275 Somatomedins Human genes 0.000 description 2
- 244000309466 calf Species 0.000 description 2
- 230000000052 comparative effect Effects 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 238000004090 dissolution Methods 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 229940088597 hormone Drugs 0.000 description 2
- 239000005556 hormone Substances 0.000 description 2
- 239000002054 inoculum Substances 0.000 description 2
- 229910052742 iron Inorganic materials 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 230000004060 metabolic process Effects 0.000 description 2
- 239000011259 mixed solution Substances 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 229960005190 phenylalanine Drugs 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 229960004441 tyrosine Drugs 0.000 description 2
- 241000701161 unidentified adenovirus Species 0.000 description 2
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 102000015731 Peptide Hormones Human genes 0.000 description 1
- 108010038988 Peptide Hormones Proteins 0.000 description 1
- 239000001888 Peptone Substances 0.000 description 1
- 108010080698 Peptones Proteins 0.000 description 1
- BELBBZDIHDAJOR-UHFFFAOYSA-N Phenolsulfonephthalein Chemical compound C1=CC(O)=CC=C1C1(C=2C=CC(O)=CC=2)C2=CC=CC=C2S(=O)(=O)O1 BELBBZDIHDAJOR-UHFFFAOYSA-N 0.000 description 1
- 230000001464 adherent effect Effects 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- 210000000227 basophil cell of anterior lobe of hypophysis Anatomy 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- FAPWYRCQGJNNSJ-UBKPKTQASA-L calcium D-pantothenic acid Chemical compound [Ca+2].OCC(C)(C)[C@@H](O)C(=O)NCCC([O-])=O.OCC(C)(C)[C@@H](O)C(=O)NCCC([O-])=O FAPWYRCQGJNNSJ-UBKPKTQASA-L 0.000 description 1
- 229960002079 calcium pantothenate Drugs 0.000 description 1
- 229940088129 calcium pantothenate 10 mg Drugs 0.000 description 1
- 235000011089 carbon dioxide Nutrition 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 229940019142 folic acid 5 mg Drugs 0.000 description 1
- 229940095491 glucose 5000 mg Drugs 0.000 description 1
- 229940026527 glycine 50 mg Drugs 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 229960003511 macrogol Drugs 0.000 description 1
- 229910021645 metal ion Inorganic materials 0.000 description 1
- 235000006180 nutrition needs Nutrition 0.000 description 1
- 230000000050 nutritive effect Effects 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- 239000000813 peptide hormone Substances 0.000 description 1
- 235000019319 peptone Nutrition 0.000 description 1
- 229960003531 phenolsulfonphthalein Drugs 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 238000001243 protein synthesis Methods 0.000 description 1
- 235000018102 proteins Nutrition 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 230000007115 recruitment Effects 0.000 description 1
- 238000012827 research and development Methods 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 230000003068 static effect Effects 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 238000004114 suspension culture Methods 0.000 description 1
- 239000011573 trace mineral Substances 0.000 description 1
- 235000013619 trace mineral Nutrition 0.000 description 1
- 230000014616 translation Effects 0.000 description 1
- 229940023356 vitamin b6 10 mg Drugs 0.000 description 1
Images
Landscapes
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
本发明涉及一种用于人胚胎肾(HEK)293细胞培养的无血清培养基,其是在现有基础培养基的基础上添加了转铁蛋白、胰岛素、Primatone、类脂混合物、氨基酸、无机盐和维生素等物质构成。该培养基能使(HEK)293细胞旺盛生长且成本低,是一种具有商业价值的细胞培养。The invention relates to a serum-free medium for culturing human embryonic kidney (HEK) 293 cells, which adds transferrin, insulin, Primatone, lipid mixture, amino acid, inorganic Composition of substances such as salt and vitamins. The culture medium can make (HEK)293 cells grow vigorously and has low cost, and is a kind of cell culture with commercial value.
Description
Technical field
The present invention relates to a kind of substratum that is used for human embryo kidney (HEK) 293 cell cultures, specifically, relate to a kind of serum free medium of the HEK293 of being used for cell cultures.
Background technology
Human embryo kidney (HEK) 293 cells are at first set up in 1977 by Graham etc., are the desirable hosts who produces recombinant adenovirus.
Traditional substratum of HEK293 cell is that blood serum medium is arranged.But, there is the use of blood serum medium to be restricted along with people improve constantly the understanding that animal serum may pollute production process even the finished product.Serum free medium, with its have passivity pollute, batch between otherness advantages such as separation and purification little and that help expression product more and more be subjected to people's attention.
The existing at present serum free medium that is fit to the HEK293 cell cultures has: 293-SFMII (Invitrogen), Ex-Cell 525 (JRH), IS293-SF (Irvine Scientific), Pro293s-CDM (Cambrex), CD293 Medium, Freestyle
TM293 and Expression Medium (Gibco) etc., but the price comparison costliness of these serum free mediums.Therefore this area presses for the serum free medium of a kind of low cost of research and development and suitable HEK293 cell cultures.
Summary of the invention
The object of the invention is, a kind of low cost is provided and has been applicable to the serum free medium of human embryo kidney (HEK) 293 cell cultures.
Design of the present invention is such:
In the serum free medium owing to lack serum, the essential blood serum substituting factor of adding, current, the recruitment factor kind of alternative serum has a lot, generally includes somatomedin, hormone, lipid, conjugated protein and trace element etc.In order to develop the serum free medium that is fit to the HEK293 cell, the present invention has added following serum substitute:
(1) Transferrins,iron complexes: a kind of glycoprotein in conjunction with iron, with the single-minded receptor acting of cell surface, transmit iron ion.
(2) Regular Insulin: beta Cell of islet excretory polypeptide hormone, promote the cell growth, regulate the metabolism of glucose and lipid.
(3) Primatone: a kind of peptone, can play stable and the active function of adjusting above-mentioned substance in anteserum-less substrate by combining with VITAMIN, lipid, metal ion, hormone and somatomedin.In the stir culture system, the mechanicalness protection effect that viscosity by influencing substratum and oncotic pressure are brought into play pair cell.
(4) lipid mixture: phosphatide is the integral part of cell, adds lipid mixture and can promote the synthetic of phosphatide, accelerates the synthetic of cytolemma, increases the slipperiness of cytolemma.
Because lack the effect of serum, corresponding variation can take place the metabolism situation of cell when serum-free culture, nutritional needs is corresponding to change, and for this reason, changes the content of composition on the basis of the nutritive ingredient of basic medium that must be when having serum to cultivate.Amino acid is the precursor of protein synthesis, and its utilization is also grown for cell and product production provides energy.Amino acid can also be alleviated the influence of generation, carbonic acid gas and the osmotic pressure of ammonia.The production of adenovirus has bigger demand to amino acid, and therefore, HEK293 cell non-serum culture medium of the present invention contains than the more amino acid of general basic medium.
The said serum free medium that is used for human embryo kidney (HEK) 293 cell cultures of the present invention is made up of amino acid, VITAMIN, inorganic salt and other parts, and it comprises following component and content:
Amino acid moiety:
L-L-Ala 0~30mg/L
L-arginine 50~300mg/L
L-L-glutamic acid 10~150mg/L
Altheine 10~200mg/L
L-aspartic acid 20~300mg/L
L-halfcystine 20~300mg/L
L-Gelucystine 50~600mg/L
L-glycine 0~50mg/L
L-Histidine 40~700mg/L
L-Isoleucine 50~700mg/L
L-leucine 80~1200mg/L
L-Methionin 90~1500mg/L
L-methionine(Met) 20~400mg/L
L-phenylalanine-3,4-quinone 0~500mg/L
L-proline(Pro) 0~50mg/L
L-Threonine 50~600mg/L
L-Serine 50~200mg/L
L-tryptophane 10~200mg/L
L-tyrosinase 15 0~800mg/L
L-Xie Ansuan 50~700mg/L
L-glutaminate 100~9000mg/L
The VITAMIN part:
Vitamin H 0.001~0.01mg/L
Choline chloride 60 5~20mg/L
VITMAIN B1 2~10mg/L
Wei ShengsuB2 0.1~0.5mg/L
Vitamin B12 0.2~1.0mg/L
Thioctic Acid 0.1~0.5mg/L
The inorganic salt part:
Fe(NO
3)
3.9H
2O 2~10mg/L
FeSO
4.7H
2O 5~20mg/L
KCl 200~500mg/L
MgCl
2 20~50mg/L
CuSO
4.5H
2O 0.001~0.01mg/L
Na
2HPO
4.2H
2O 50~100mg/L
NaH
2PO
4.2H
2O 50~100mg/L
Sodium Selenite 0.005~0.05mg/L
NaHCO
3 2000mg/L
NaCl 6999.5mg/L
MgSO
4 30~50mg/L
ZnSO
4.7H
2O 0.2~0.5mg/L
Other parts:
Glucose 2000~5000mg/L
Transferrins,iron complexes 2~20mg/L
Primatone 1000~5000mg/L
Lipid mixture 0.1v/v%~0.5v/v%
Hydrocortisone 0.05~0.5mg/L
HEPES 1000~5000mg/L
Pluronic F-68 1~10g/L
Dextran 10~100mg/L
Reduced glutathion 0~3mg/L
Thymus pyrimidine 0.3~0.5mg/L
Wherein: the lipid that the chemical ingredients that said lipid mixture is produced for GIBCO company is determined, it is composed as follows
Arachidonic acid 2mg/L
1
Cholesterol 220mg/L
1
DL-alpha-tocopherol acetate 70mg/L
1
Linolic acid 10mg/L
1
Linolenic acid 10mg/L
1
Myristic acid 10mg/L
1
Oleic acid 10mg/L
1
Physetoleic acid 10mg/L
1
Palmitinic acid 10mg/L
1
Stearic acid 10mg/L
1
Tween 80 2200mg/L
1
Pluronic F-68 100000mg/L
1
L is the cumulative volume of said serum free medium, L
1Be the overall integrating of said lipid mixture, the molecular weight of used polyoxyethylene glycol is 20000.
Above-mentioned related raw material is commercially available product, and wherein Primatone, HEPES and Pluronic F-68 are all available from Sigma company.
The key step of preparation the present invention said serum free medium is: with above-mentioned raw materials according to its dissolution characteristics classification dissolving separately, then with gained solution in 20~30 ℃ of mixing, make each component concentration as listed above, regulate the pH value to 7.2 of gained mixed solution, promptly get target compound behind the constant volume.
The using method of the said serum free medium of the present invention is identical with the using method of existing serum free medium.
Description of drawings
Fig. 1 is the test-results diagram of embodiment 2 and Comparative Examples 1.
Wherein: the cell density of the substratum of ◇-employing DMEM+10% foetal calf serum;
◆-the adopt cell density of serum free medium.
Embodiment
Below by embodiment content of the present invention is further described, its purpose only is better to understand content of the present invention and unrestricted protection scope of the present invention.
The said preparation that is used for the serum free medium of human embryo kidney (HEK) 293 cell cultures of the present invention:
With following raw materials according according to its dissolution characteristics classification dissolving (being undertaken) separately by the operation steps that supplier provides, then with gained solution in 20~30 ℃ of mixing, make each component concentration following listed, regulate the pH value to 7.2 of gained mixed solution, promptly get target compound behind the constant volume.
Amino acid moiety:
The name of an article | mg/L |
The L-tryptophane | 20 |
The L-halfcystine | 30 |
The L-Gelucystine | 60 |
L-tyrosine | 70 |
The L-Isoleucine | 90 |
The L-leucine | 120 |
The L-Xie Ansuan | 92 |
L-L-glutamic acid | 14.5 |
Altheine | 15 |
The L-glycine | 18.75 |
The L-proline(Pro) | 17.25 |
The L-L-Ala | 4.45 |
The L-arginine | 14.75 |
The L-aspartic acid | 30 |
The L-Histidine | 62.75 |
L-Methionin | 275 |
The L-methionine(Met) | 26.68 |
The L-phenylalanine | 54.8 |
The L-Serine | 87.5 |
L-glutaminate | 584 |
The L-Threonine | 54.5 |
The inorganic salt part:
The name of an article | mg/L |
KCl | 311.8 |
MgCl 2 | 28.61 |
MgSO 4 | 48.84 |
ZnSO 4.7H 2O | 0.432 |
CuSO 4.5H 2O | 0.001 |
CaCl 2 | 2.220 |
Na 2HPO 4.2H 2O | 89.025 |
NaH 2PO 4.2H 2O | 70.65 |
Ironic citrate | 6.1225 |
Fe(NO 3) 3.9H 2O | 2.050 |
FeSO 4.7H 2O | 3.417 |
NaF | 4.2 |
NaHCO 3 | 2000 |
NaCl | 6999.5 |
Sodium Selenite | 0.005 |
The VITAMIN part:
The name of an article | mg/L |
Calcium pantothenate | 2.24 |
Choline chloride 60 | 8.89 |
Folic acid | 2.65 |
Inositol | 12.6 |
Niacinamide | 2.0 |
Vitamin B6 | 2.0 |
VITMAIN B1 | 4.17 |
Wei ShengsuB2 | 0.219 |
Vitamin B12 | 0.68 |
Vitamin H | 0.0037 |
Thioctic Acid | 0.1 |
Other parts:
The name of an article | mg/L |
Reduced glutathion | 0.75 |
Xanthoglobulin | 4.39 |
Thymus pyrimidine | 0.365 |
Regular Insulin | 20 |
Transferrins,iron complexes | 20 |
Macrogol 2000 0 | 2 |
Primatone | 4000 |
Lipid mixture | 0.2%(v/v) |
Hydrocortisone | 0.05 |
Glucose | 4500 |
HEPES | 4000 |
Pluronic F-68 | 1000 |
Dextran | 100 |
Phenol red | 10 |
By making the serum free medium that another kind is used for human embryo kidney (HEK) 293 cell cultures with embodiment 1 described method: its composition and content are as follows:
L-L-Ala 30mg/L
L-arginine 300mg/L
L-L-glutamic acid 150mg/L
Altheine 200mg/L
L-aspartic acid 300mg/L
L-halfcystine 300mg/L
L-Gelucystine 600mg/L
L-glycine 50mg/L
L-Histidine 700mg/L
L-Isoleucine 700mg/L
L-leucine 1200mgL
L-Methionin 1500mg/L
L-methionine(Met) 400mg/L
L-phenylalanine 500mg/L
L-proline(Pro) 50mg/L
L-Threonine 600mg/L
L-Serine 200mg/L
L-tryptophane 200mg/L
L-tyrosine 800mg/L
L-Xie Ansuan 700mg/L
L-glutaminate 9000mg/L
The VITAMIN part:
Vitamin H 0.01mg/L
Choline chloride 60 20mg/L
Calcium pantothenate 10mg/L
Folic acid 5mg/L
Inositol 20mg/L
VITMAIN B1 10mg/L
Wei ShengsuB2 0.5mg/L
Vitamin B6 10mg/L
Vitamin B12 1.0mg/L
Niacinamide 5mg/L
Thioctic Acid 0.5mg/L
The inorganic salt part:
Ironic citrate 20mg/L
NaF 20mg/L
Fe(NO
3)
3.9H
2O 10mg/L
FeSO
4.7H
2O 20mg/L
KCl 500mg/L
MgCl
2 50mg/L
CuSO
4.5H
2O 0.01mg/L
CaCl
2 200mg/L
Na
2HPO
4.2H
2O 100mg/L
NaH
2PO
4.2H
2O 100mg/L
Sodium Selenite 0.05mg/L
NaHCO
3 2000mg/L
NaCl 6999.5mg/L
MgSO
4 50mg/L
ZnSO
4.7H
2O 0.5mg/L
Other parts:
Glucose 5000mg/L
Regular Insulin 20mg/L
Transferrins,iron complexes 20mg/L
Polyoxyethylene glycol (20000) 10mg/L
Primatone 5000mg/L
Lipid mixture 0.5v/v%
Hydrocortisone 0.5mg/L
HEPES 5000mg/L
Pluronic F-68 10g/L
Dextran 100mg/L
Reduced glutathion 3mg/L
Xanthoglobulin 10mg/L
Thymus pyrimidine 0.5mg/L
Cultivate the HEK293 cell that has adapted to the serum-free suspension culture in the square vase of 125ml, inoculum density is 3 * 10
5Cells/ml, liquid amount are 20ml, and the square vase that will connect seed cell again places shaking table, and (model: TZ-03, (shaking table is placed on 36.5 ℃, 5%CO SHENERGYBIOCOLOR) to go up cultivation
2In the incubator), rotating speed is 120r/min, cultivates 5 days, maximum cell density reaches 3.8 * 10
6Cells/ml.Result such as Fig. 1.The serum free medium that present embodiment uses is made by embodiment 1.
Comparative Examples 1
Cultivate adherent HEK293 cell in the square vase of 125ml, inoculum density is 3 * 10
5Cells/ml, square vase are placed on 36.5 ℃, 5%CO
2In the incubator, different is: the substratum of adding is DMEM+10% foetal calf serum (FBS), and liquid amount is 10ml, and static cultivation was cultivated 5 days, and maximum cell density is 2.6 * 10
6Cells/ml.Result such as Fig. 1, serum free medium of the present invention are suitable for HEK293 cell high-density growth.
Claims (1)
1, a kind of serum free medium that is used for human embryo kidney (HEK) 293 cell cultures is made up of amino acid, VITAMIN, inorganic salt and other parts, it is characterized in that said serum free medium comprises following component and content:
Amino acid moiety:
L-L-Ala 0~30mg/L
L-arginine 50~300mg/L
L-L-glutamic acid 10~150mg/L
Altheine 10~200mg/L
L-aspartic acid 20~300mg/L
L-halfcystine 20~300mg/L
L-Gelucystine 50~600mg/L
L-glycine 0~50mg/L
L-Histidine 40~700mg/L
L-Isoleucine 50~700mg/L
L-leucine 80~1200mg/L
L-Methionin 90~1500mg/L
L-methionine(Met) 20~400mg/L
L-phenylalanine-3,4-quinone 0~500mg/L
L-proline(Pro) 0~50mg/L
L-Threonine 50~600mg/L
L-tryptophane 10~200mg/L
L-tyrosinase 15 0~800mg/L
L-Xie Ansuan 50~700mg/L
L-glutaminate 100~9000mg/L
The VITAMIN part:
Vitamin H 0.001~0.01mg/L
Choline chloride 60 5~20mg/L
Calcium pantothenate 2~10mg/L
Folic acid 0~5mg/L
Inositol 5~20mg/L
VITMAIN B1 2~10mg/L
Wei ShengsuB2 0.1~0.5mg/L
Vitamin B6 2~10mg/L
Vitamin B12 0.2~1.0mg/L
Niacinamide 2~5mg/L
The inorganic salt part:
Ironic citrate 5~20mg/L
NaF 2~20mg/L
Fe(NO
3)
3.9H
2O 2~10mg/L
FeSO
4.7H
2O 5~20mg/L
KCl 200~500mg/L
MgCl
2 20~50mg/L
CuSO
4.5H
2O 0.001~0.01mg/L
CaCl
2 2~200mg/L
Na
2HPO
4.2H
2O 50~100mg/L
NaH
2PO
4.2H
2O 50~100mg/L
Sodium Selenite 0.005~0.05mg/L
NaHCO
3 2000mg/L
NaCl 6999.5mg/L
Other parts:
Glucose 2000~5000mg/L
Regular Insulin 2~20mg/L
Transferrins,iron complexes 2~20mg/L
Polyoxyethylene glycol 2~10mg/L
Primatone 1000~5000mg/L
Lipid mixture 0.1v/v%~0.5v/v%
Hydrocortisone 0.05~0.5mg/L
HEPES 1000~5000mg/L
Pluronic F-68 1~10g/L
Dextran 10~100mg/L
Reduced glutathion 0~3mg/L
Wherein: the lipid that the chemical ingredients that said lipid mixture is produced for GIBCO company is determined, it is composed as follows
Arachidonic acid 2mg/L
1
Cholesterol 220mg/L
1
DL-alpha-tocopherol acetate 70mg/L
1
Linolic acid 10mg/L
1
Linolenic acid 10mg/L
1
Myristic acid 10mg/L
1
Oleic acid 10mg/L
1
Physetoleic acid 10mg/L
1
Palmitinic acid 10mg/L
1
Stearic acid 10mg/L
1
Tween 80 2200mg/L
1
Pluronic F-68 100000mg/L
1
L is the cumulative volume of said serum free medium, and L1 is the overall integrating of said lipid mixture, and the molecular weight of used polyoxyethylene glycol is 20000.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CNB2006100301108A CN100569940C (en) | 2006-08-16 | 2006-08-16 | Serum-free medium for human embryonic kidney (HEK) 293 cells |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CNB2006100301108A CN100569940C (en) | 2006-08-16 | 2006-08-16 | Serum-free medium for human embryonic kidney (HEK) 293 cells |
Publications (2)
Publication Number | Publication Date |
---|---|
CN1908162A true CN1908162A (en) | 2007-02-07 |
CN100569940C CN100569940C (en) | 2009-12-16 |
Family
ID=37699393
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CNB2006100301108A Expired - Fee Related CN100569940C (en) | 2006-08-16 | 2006-08-16 | Serum-free medium for human embryonic kidney (HEK) 293 cells |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN100569940C (en) |
Cited By (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN104357379A (en) * | 2014-09-30 | 2015-02-18 | 刘兴宇 | Stem cell culture medium |
CN104651297A (en) * | 2013-11-19 | 2015-05-27 | 华东师范大学 | Culture medium used in high-density large-scale suspended cultivation of human embryo nephrocyte, preparation method and application thereof |
CN105647852A (en) * | 2016-03-30 | 2016-06-08 | 北京普瑞金科技有限公司 | Method for serum-free culturing of 293T cells for lentivirus package |
CN104450607B (en) * | 2014-11-14 | 2017-07-11 | 武汉金开瑞生物工程有限公司 | For the full chemistry culture medium and cultural method of HEK293 cell suspension growths |
JP2018183154A (en) * | 2012-04-24 | 2018-11-22 | ジェネンテック, インコーポレイテッド | Cell culture compositions and methods for polypeptide production |
CN111793595A (en) * | 2020-07-23 | 2020-10-20 | 上海奥浦迈生物科技有限公司 | Serum-free culture medium for HEK293 cells |
CN111826341A (en) * | 2020-07-23 | 2020-10-27 | 上海奥浦迈生物科技有限公司 | Method for in vitro culture of HEK293 cells for transient expression of proteins |
CN112501113A (en) * | 2021-02-03 | 2021-03-16 | 上海奥浦迈生物科技股份有限公司 | HEK293 cell combined gradient culture medium and application thereof |
CN113061584A (en) * | 2021-05-14 | 2021-07-02 | 赵峻岭 | Culture medium additive capable of promoting growth of adenovirus |
CN114438131A (en) * | 2022-02-25 | 2022-05-06 | 上海健士拜生物科技有限公司 | 293 cell transfection method |
CN114736871A (en) * | 2022-04-27 | 2022-07-12 | 中山康晟生物技术有限公司 | Adenovirus packaging WAYNE293LVPRO animal cell culture method |
CN114836367A (en) * | 2022-04-28 | 2022-08-02 | 上海东富龙生物试剂有限公司 | Chemical component limited culture medium for HEK293 cell culture and adenovirus and adeno-associated virus replication and amplification |
CN115369069A (en) * | 2022-08-22 | 2022-11-22 | 上海健士拜生物科技有限公司 | 293 cell feed culture medium and preparation and application thereof |
US11661579B2 (en) | 2007-04-26 | 2023-05-30 | Chugai Seiyaku Kabushiki Kaisha | Cell culture method using amino acid-enriched medium |
-
2006
- 2006-08-16 CN CNB2006100301108A patent/CN100569940C/en not_active Expired - Fee Related
Cited By (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US11661579B2 (en) | 2007-04-26 | 2023-05-30 | Chugai Seiyaku Kabushiki Kaisha | Cell culture method using amino acid-enriched medium |
JP2018183154A (en) * | 2012-04-24 | 2018-11-22 | ジェネンテック, インコーポレイテッド | Cell culture compositions and methods for polypeptide production |
JP7323272B2 (en) | 2012-04-24 | 2023-08-08 | ジェネンテック, インコーポレイテッド | Cell culture compositions and methods for polypeptide production |
JP2021104023A (en) * | 2012-04-24 | 2021-07-26 | ジェネンテック, インコーポレイテッド | Cell culture composition and method for polypeptide production |
CN104651297A (en) * | 2013-11-19 | 2015-05-27 | 华东师范大学 | Culture medium used in high-density large-scale suspended cultivation of human embryo nephrocyte, preparation method and application thereof |
CN104357379B (en) * | 2014-09-30 | 2017-08-08 | 刘兴宇 | Stem cell media |
CN104357379A (en) * | 2014-09-30 | 2015-02-18 | 刘兴宇 | Stem cell culture medium |
CN104450607B (en) * | 2014-11-14 | 2017-07-11 | 武汉金开瑞生物工程有限公司 | For the full chemistry culture medium and cultural method of HEK293 cell suspension growths |
CN105647852A (en) * | 2016-03-30 | 2016-06-08 | 北京普瑞金科技有限公司 | Method for serum-free culturing of 293T cells for lentivirus package |
CN111793595A (en) * | 2020-07-23 | 2020-10-20 | 上海奥浦迈生物科技有限公司 | Serum-free culture medium for HEK293 cells |
CN111826341A (en) * | 2020-07-23 | 2020-10-27 | 上海奥浦迈生物科技有限公司 | Method for in vitro culture of HEK293 cells for transient expression of proteins |
CN112501113A (en) * | 2021-02-03 | 2021-03-16 | 上海奥浦迈生物科技股份有限公司 | HEK293 cell combined gradient culture medium and application thereof |
CN113061584A (en) * | 2021-05-14 | 2021-07-02 | 赵峻岭 | Culture medium additive capable of promoting growth of adenovirus |
CN114438131A (en) * | 2022-02-25 | 2022-05-06 | 上海健士拜生物科技有限公司 | 293 cell transfection method |
CN114736871A (en) * | 2022-04-27 | 2022-07-12 | 中山康晟生物技术有限公司 | Adenovirus packaging WAYNE293LVPRO animal cell culture method |
CN114836367A (en) * | 2022-04-28 | 2022-08-02 | 上海东富龙生物试剂有限公司 | Chemical component limited culture medium for HEK293 cell culture and adenovirus and adeno-associated virus replication and amplification |
CN115369069A (en) * | 2022-08-22 | 2022-11-22 | 上海健士拜生物科技有限公司 | 293 cell feed culture medium and preparation and application thereof |
CN115369069B (en) * | 2022-08-22 | 2023-12-19 | 上海健士拜生物科技有限公司 | 293 cell feed supplement culture medium and preparation and application thereof |
Also Published As
Publication number | Publication date |
---|---|
CN100569940C (en) | 2009-12-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN1908162A (en) | Serum-free culture medium of human embryo kidney (HEK) 293 cell | |
CA2797356C (en) | Improved cell culture medium | |
CN1303991C (en) | Stabilized pharmaceutical preparations of gamma-aminobutyric acid derivative process for preparing the same | |
CN1249223C (en) | Method for cultivating cancer cells from human tissue and device for preparing tissue samples | |
CN101418330B (en) | Non protein culture medium adapted to large-scale culture of NSO cell and production of antibody | |
EP2563903B1 (en) | Improved cell culture medium | |
CN101057635A (en) | Low-salinity autumn and winter cultivation ecological bait for litopenaeus vannamei and its preparation method | |
CN1854303A (en) | Method for the production of S-adenosylmethionine by fermentation | |
CN1919363A (en) | Novel dialytic concentrating preparation | |
CN101052708A (en) | Serum-free cell culture medium for mammalian cells | |
CN1024809C (en) | Method for producing useful substance using microorganism having low acetic acid-forming ability | |
CN1696283A (en) | A serum-free medium suitable for Chinese hamster ovary cell culture | |
CN1458973A (en) | Pre-adipose cell lines | |
CN1238498C (en) | Method for parameter control of the process for culturing serum-suspension free animal cell | |
CN1915222A (en) | Composition of liposome, and preparation method | |
CN1193091C (en) | Serumless medium suitable for growth and maintenance of young hamster kidney cell | |
CN1840177A (en) | Injection liquid of thymic peptide alpha 1 and preparation method thereof | |
CN1840171A (en) | Chronic kidney disease nutrient solution and preparation method thereof | |
CN112063578B (en) | Culture medium suitable for full-suspension cell culture and preparation method and application thereof | |
CN101036642A (en) | Ginkgolide B nanometric liposomes medicine and the preparing method thereof | |
CN1180080C (en) | An improved preparation method of liver cancer mouse monoclonal antibody | |
CN114250191B (en) | Serum-free culture medium suitable for high-density culture and high-expression of insect cells | |
CN1927925A (en) | Preparation method of large particle size butyronitrile latex | |
CN1867665A (en) | Myeloma cell culture in transferrin-free low iron medium | |
CN1593199A (en) | Method for producing soy bean peptide liquid food and biosis bacteria tablet using soy bean fermentation |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20091216 Termination date: 20140816 |
|
EXPY | Termination of patent right or utility model |